MedTrace Logo

Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE)

NCT04402385 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-07-11

Study results available
· View outcomes & findings →

Summary

To determine if low dose aspirin reduces the incidence of hypertensive disorders of pregnancy (gestational hypertension, preeclampsia, eclampsia, and HELLP syndrome) in pregnant women with stage 1 hypertension and elevated blood pressure.

Conditions

  • Pre-Eclampsia
  • Stage 1 Hypertension
  • Elevated Blood Pressure

Interventions

DRUG

Aspirin 81 mg

Participants randomized to 81 mg of Aspirin daily

DRUG

Placebo

Participants randomized to placebo daily

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Olga Grechukhina, MD · Yale University

  • Hillart Hosier, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-06
Primary Completion
2022-06-22
Completion
2022-06-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04402385 on ClinicalTrials.gov